Comparative Pharmacology
Head-to-head clinical analysis: BORTEZOMIB versus KYPROLIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BORTEZOMIB versus KYPROLIS.
BORTEZOMIB vs KYPROLIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibition of the 26S proteasome, disrupting protein homeostasis and leading to apoptosis in cancer cells.
Carfilzomib is an irreversible inhibitor of the proteasome, a large protease complex that degrades ubiquitinated proteins. By blocking proteasome function, carfilzomib disrupts protein homeostasis, leading to accumulation of misfolded proteins, activation of the unfolded protein response, endoplasmic reticulum stress, and ultimately apoptosis, particularly in myeloma cells with high protein turnover.
1.3 mg/m2 intravenously or subcutaneously twice weekly for 2 weeks (days 1, 4, 8, 11) followed by a 10-day rest period (days 12-21) for cycles 1-8; for cycles 9-16, administer once weekly on days 1, 8, 15, 22 followed by a 13-day rest period.
20 mg/m² IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle; increase to 27 mg/m² on day 8 of cycle 1 if tolerated.
None Documented
None Documented
Clinical Note
moderateBortezomib + Digoxin
"Bortezomib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateBortezomib + Digitoxin
"Bortezomib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateBortezomib + Deslanoside
"Bortezomib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateBortezomib + Acetyldigitoxin
"Bortezomib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life 40-100 hours (mean ~76 hours); supports twice-weekly dosing schedule.
Terminal elimination half-life of 1.3 to 2.1 hours (mean 1.5 hours), supporting continuous infusion scheduling
Primarily hepatic metabolism via CYP3A4 and CYP2C19; <10% excreted unchanged in urine; fecal elimination accounts for ~40% of total clearance.
Primarily hepatic metabolism; less than 2% of the dose is excreted unchanged in urine and feces combined
Category D/X
Category C
Proteasome Inhibitor
Proteasome Inhibitor